Chronic obstructive pulmonary disease (COPD) weakens the structure of the lung and may also damage the tiny air sacs (alveoli) in the lung. When these air sacs break down, larger airspaces known as bullae are formed.
Bullae sometimes can become so large that they interfere with breathing and may cause complications:
- They can burst, leading to a collapsed lung (pneumothorax). A collapsed lung will often need treatment with a chest tube.
- They can become infected, leading to an abscess in the lung that can spread to the pleural cavity (the space between the lung and the membrane that surrounds it). This condition (empyema) can be difficult to resolve and often requires extensive treatment with antibiotics.
For some people, surgically removing the enlarged air sacs—known as a bullectomy—makes breathing easier. However, few people are considered good candidates for a bullectomy. It may work best for people with COPD who are young, have large bullae that are grouped in just one area of the lung, and do not have severe blockage in their airways.1 A bullectomy may be considered if the bullae:
- Are larger than one-third of a lung.
- Prevent the lung from expanding so the person cannot move enough air into his or her lungs.
Bullectomy may make the lungs work better so more oxygen gets into the blood.
If there are many bullae spread throughout the lungs, surgery is not likely to be helpful. In this case, other areas of the lung often become damaged after the surgery. The best surgical results are obtained when there is only one bulla or only a few that are all clustered in one area.
Long-term follow-up studies have begun to show that within 3 to 5 years after surgery, lung function deteriorates to the level it was before surgery.2
The decision about whether to perform the surgery is difficult and usually is based on the doctor's experience and the person's overall condition.
Bullae can be removed using a laser, but this method has not been found to have an advantage over traditional surgery.
References
Citations
Barnes PJ (2000). Nonantimicrobial aspects of therapy. Seminars in Respiratory Infections, 15(1): 52–58.
Hanania NA, et al. (2003). The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus Inhaler for the treatment of COPD. Chest, 124: 834–843.
Credits
| Author | Lila Havens |
| Author | Robin Parks, MS |
| Editor | Kathleen M. Ariss, MS |
| Editor | Katy E. Magee, MA |
| Associate Editor | Michele Cronen |
| Associate Editor | Tracy Landauer |
| Associate Editor | Pat Truman |
| Primary Medical Reviewer | Renée M. Crichlow, MD - Family Medicine |
| Primary Medical Reviewer | Kathleen Romito, MD - Family Medicine |
| Specialist Medical Reviewer | Ken Y. Yoneda, MD - Pulmonology |
| Last Updated | June 16, 2006 |
Robin Parks, MS
© 1995-2007, Healthwise, Incorporated, P.O. Box 1989, Boise, ID 83701. ALL RIGHTS RESERVED.
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information. For more information, click here. Privacy Policy. How this information was developed.
